Status:
RECRUITING
Cardiotoxicity in Breast Cancer Patients
Lead Sponsor:
Helwan University
Conditions:
Breast Cancer
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The goal of this clinical trial is to learn if dapagliflozin drug has a cardioprotective effect against anthracyclines-induced cardiotoxicity. It will also learn about the safety of dapagliflozin drug...
Detailed Description
Breast cancer is a malignant tumor that originates in the cells of the breast tissue. It is the most common cancer in women worldwide, accounting for 24.2% of all cancer cases among women. According ...
Eligibility Criteria
Inclusion
- patients with pathologically proved invasive breast carcinoma.
- Patients were indicated for anthracyclines containing adjuvant chemotherapy or new adjuvant anthracyclines.
- Renal function (eGFR \> 30 mL/minute per 1.73 m2 )
- LVEF is more than 50 %
- Age ≥ 18 and ≤ 60 years old
Exclusion
- patients with any cardiac condition that contraindicate the use of anthracyclines, like heart failure, arrythmia, stroke and myocardial infarction.
- Previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens
- pregnant or breastfeeding patients
- patients receiving any other cardiotoxic agents.
- Patients with diabetic ketoacidosis or patients with type 1 diabetes mellitus.
- Mediastinal irradiation including heart.
- Refusal to sign the written informed consent.
Key Trial Info
Start Date :
September 10 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06491680
Start Date
September 10 2024
End Date
June 1 2026
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al demerdash hospital at oncology departement
Cairo, Cairo Governorate, Egypt, 202